论文部分内容阅读
目的:观察应用全反式维甲酸(ATRA)和三氧化二砷(As2O3)诱导并联合蒽环类药物化疗治疗急性早幼粒细胞白血病(APL)的疗效。方法:对31例急性早幼粒细胞白血病(APL)患者采用全反式维甲酸(ATRA)和三氧化二砷(As2O3)诱导治疗,缓解后序贯化疗方案为蒽环类加Ara-C(阿糖胞苷)、DA(柔红霉素+阿糖胞苷)、HA(高三尖杉酯硷+阿糖胞苷)、MDAra-C(小剂量阿糖胞苷)。结果:31例患者中,29例获得完全缓解,CR率93.54%,达到CR的平均时间为(28.52±5.14)d,1例死于颅内出血。结论:全反式维甲酸(ATRA)联合三氧化二砷(As2O3)治疗急性早幼粒细胞白血病达到完全缓解的时间短、副作用少、疗效确切,患者耐受性较好。
OBJECTIVE: To observe the efficacy of all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) in combination with anthracycline chemotherapy in the treatment of acute promyelocytic leukemia (APL). Methods: Thirty-one patients with acute promyelocytic leukemia (APL) were treated with all-trans retinoic acid (ATRA) and arsenic trioxide (As2O3). The sequential chemotherapy regimen was anthracycline plus Ara-C DA (daunorubicin + cytarabine), HA (homoharringtonine + cytarabine), MDAra-C (low dose cytarabine). Results: Of the 31 patients, 29 achieved complete remission, with a CR rate of 93.54%. The mean time to CR was (28.52 ± 5.14) days and 1 patient died of intracranial hemorrhage. CONCLUSION: All-trans retinoic acid (ATRA) and arsenic trioxide (As2O3) are effective in treating acute promyelocytic leukemia with short response time, less side effects and definite curative effect.